Occurrence and Risk Factors of Adverse Drug Reactions in Patients Receiving Bivalirudin as Anticoagulant During Percutaneous Coronary Intervention: A Prospective, Multi-Center, Intensive Monitoring Study

BACKGROUND: Bivalirudin is a common anticoagulant during percutaneous coronary intervention (PCI); however, since its application in China, it still lacks comprehensive evaluation of adverse events (AEs) or adverse drug reactions (ADRs) under the real-clinical setting conditions with a large-sample-...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ping, Zhang, Hongyan, Luo, Caidong, Ji, Zheng, Zheng, Zeqi, Li, Zhenyong, Wu, Fan, Li, Jinlong, Hong, Lang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099409/
https://www.ncbi.nlm.nih.gov/pubmed/35573935
http://dx.doi.org/10.3389/fcvm.2021.781632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099409/
https://www.ncbi.nlm.nih.gov/pubmed/35573935
http://dx.doi.org/10.3389/fcvm.2021.781632

Ejemplares similares